Publications by authors named "S D Selcuklu"
Article Synopsis
- A program was launched to provide free genomic testing for patients with rare cancers worldwide, specifically targeting histiocytosis, germ cell tumors (GCT), and pediatric cancers.
- Patients were recruited through social media and advocacy groups, and 333 were enrolled, with 288 providing tumor tissue for analysis, resulting in significant clinical benefits for patients receiving genomically guided therapy.
- The study highlighted the rarity of actionable genomic alterations in ovarian GCTs and demonstrated that direct outreach can effectively build cohorts for studying rare cancers' genomic landscapes.
The clinical success of EGFR inhibitors in EGFR-mutant lung cancer is limited by the eventual development of acquired resistance. We hypothesize that enhancing apoptosis through combination therapies can eradicate cancer cells and reduce the emergence of drug-tolerant persisters. Through high-throughput screening of a custom library of ∼1,000 compounds, we discover Aurora B kinase inhibitors as potent enhancers of osimertinib-induced apoptosis.
View Article and Find Full Text PDFPurpose: Fibroblast growth factor receptor (FGFR) 2 alterations, present in 5%-15% of intrahepatic cholangiocarcinomas (IHC), are targets of FGFR-directed therapies. Acquired resistance is common among patients who respond. Biopsies at the time of acquired resistance to targeted agents may not always be feasible and may not capture the genetic heterogeneity that could exist within a patient.
View Article and Find Full Text PDFBackground: Cell-free DNA (cfDNA) profiling is increasingly used to guide cancer care, yet mutations are not always identified. The ability to detect somatic mutations in plasma depends on both assay sensitivity and the fraction of circulating DNA in plasma that is tumor-derived (i.e.
View Article and Find Full Text PDFPurpose: Although primary germ cell tumors (GCTs) have been extensively characterized, molecular analysis of metastatic sites has been limited. We performed whole-exome sequencing and targeted next-generation sequencing on paired primary and metastatic GCT samples in a patient cohort enriched for cisplatin-resistant disease.
Patients And Methods: Tissue sequencing was performed on 100 tumor specimens from 50 patients with metastatic GCT, and sequencing of plasma cell-free DNA was performed for a subset of patients.